Five years and five more approved drugs later, RNAi therapeutics are a proven class of medicines, and the potential for further innovation remains. “This is changing the practice of medicine ...

In 2008, researchers were making great strides in what’s known as RNAi therapy. RNAi stands for RNA interference. It is the natural process of gene silencing.RNAi therapy is the synthetic ...

2025年2月19日，中国科学院生物物理研究所范克龙和阎锡蕴团队在《Science Advances》期刊上发表题为"Bioengineered protein nanocarrier facilitating siRNA escape from ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

Scientists seek innovative approaches to address this health crisis, some of which are therapeutics poised to treat CVD in new ways. RNA interference (RNAi) therapeutics silence genes, disrupting the ...

RNAi therapeutics work by silencing gene expression, and thereby intercept a disease a stage earlier than most existing drugs - rather than binding to proteins which cause diseases, the drugs ...

据药渡企业洞察统计，（01月27日---02月09日）大健康领域共披露投融资事件 13 起，其中 11 起融资披露了融资金额和币种信息，总规模 超5亿元人民币 。 按照金额划分： 亿元及以上（以人民币计）事件 6 起，最高金额来自Atalanta ...

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...

周四，Jefferies分析师Kelly Shi调整了专注于RNA干扰（RNAi）疗法治疗重症的生物科技公司Silence Therapeutics（NASDAQ:SLN）的目标价。新目标价设定为30.00美元，较此前的31.00美元略有下调，但维持对该公司股票的"买入"评级。目前该股交易价格为4.72美元，过去一年下跌超过81%，尽管 InvestingPro ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...